Guest Column

China's losers from healthcare reform

  • Published 09 Sep 2010

Jonathan Zifferblatt, managing director of General Biologic, talks on the challenges facing China's healthcare and pharmaceutical industry following the implementation of healthcare reform.

Healthcare reform, when announced by the Chinese government in 2008, met with predictably mixed reactions from various stakeholders in China’s medical and pharmaceutical sectors.

Subscribe now to access all of China Confidential

China Confidential Funds

China Confidential Funds, a new research service launched by FT China Confidential, is dedicated to illuminating the mainland fund industry. Our team of fund industry experts in Shanghai search out the interesting trends in fund performance, strategy, interactions with overseas funds, regulatory changes, distribution and management. We also use a proprietary system to track the emerging flows of Chinese money. Click here to find out more.

Find out more